Paliperidone 6-Month Im Injection Suppliers & Bulk Manufacturers
Available Forms: Once-6-Month IM Injection
Available Strengths: 1,092 mg, 1,560 mg
Reference Brands: Invega Hafyera®(US)
Category: Antipsychotropic Drugs
Paliperidone 6-Month IM Injection is available in Once-6-Month IM Injection and strengths such as 1,092 mg, 1,560 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Paliperidone 6-Month IM Injection is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
| Technical Specifications & Supply Details | |
|---|---|
| Lead Time | 7 to 60 days (depending on batch size & schedule) |
| MOQ | As per manufacturer’s batch size |
| COA | Available with every batch |
| Regulatory Dossier / DMF | Available upon request |
| Export Documentation | FSC, COA, Manufacturing License, Product Permission |
| Standards | IP, BP, USP |
| Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Paliperidone 6-Month IM Injection can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
Product Description: Paliperidone 6-month intramuscular injection (brand name: Invega Hafyera) is FDA-approved in the United States for the maintenance treatment of schizophrenia in adults stabilized on 1-month or 3-month paliperidone formulations. It is designed to improve adherence and reduce relapse by offering long-term dosing. In the European Union, this 6-month version is not yet widely approved, requiring a new EMA submission via the centralized procedure. Regulatory requirements include GMP-compliant long-acting injectable technology, bridging pharmacokinetic studies, and thorough safety evaluations. U.S. labelling carries boxed warnings for elderly dementia-related psychosis. Explore sourcing options at Pharmatradz.com — your B2B pharma partner.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Related Products
Clorazepate Dipotassium
Strength:
3.75 mg, 7.5 mg, 15 mg, 5 mg, 10 mg, 20 mg
Form: Tablets, Capsules
Reference Brands: Tranxene (USA), Tranxilium(EU)
View Details
Lumateperone
Strength:
10.5 mg, 21 mg, 42 mg
Form: Capsules
Reference Brands: Caplyta (USA)
View Details
Amoxapine
Strength:
25 mg, 50 mg, 100 mg, 150 mg
Form: Tablets
Reference Brands: Generic formulations marketed under different names
View Details
Amisulpride
Strength:
5 mg/2 mL, 50 mg, 100 mg, 200 mg
Form: Tablets / injectable solutions
Reference Brands: Barhemsys (USA), Solian (EU)
View DetailsQuick Response Guaranteed | Verified Suppliers
